Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/ multidrug resistance-associated protein 2, OATP1B1/multi by Soichiro Matsushima et al.
Identification of the Hepatic Efflux Transporters of Organic
Anions Using Double-Transfected Madin-Darby Canine Kidney
II Cells Expressing Human Organic Anion-Transporting
Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated
Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/
Breast Cancer Resistance Protein
Soichiro Matsushima, Kazuya Maeda, Chihiro Kondo, Masaru Hirano, Makoto Sasaki,
Hiroshi Suzuki, and Yuichi Sugiyama
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Received February 28, 2005; accepted May 17, 2005
ABSTRACT
Until recently, it was generally believed that the transport of
various organic anions across the bile canalicular membrane
was mainly mediated by multidrug resistance-associated
protein 2 (MRP2/ABCC2). However, a number of new reports
have shown that some organic anions are also substrates of
multidrug resistance 1 (MDR1/ABCB1) and/or breast cancer
resistance protein (BCRP/ABCG2), implying MDR1 and BCRP
could also be involved in the biliary excretion of organic anions
in humans. In the present study, we constructed new double-
transfected Madin-Darby canine kidney II (MDCKII) cells ex-
pressing organic anion-transporting polypeptide 1B1
(OATP1B1)/MDR1 and OATP1B1/BCRP, and we investigated
the transcellular transport of four kinds of organic anions, es-
tradiol-17-D-glucuronide (EG), estrone-3-sulfate (ES), prava-
statin (PRA), and cerivastatin (CER), to identify which efflux
transporters mediate the biliary excretion of compounds using
double-transfected cells. We observed the vectorial transport
of EG and ES in all the double transfectants. MRP2 showed the
highest efflux clearance of EG among these efflux transporters,
whereas BCRP-mediated clearance of ES was the highest in
these double transfectants. In addition, two kinds of 3-hydroxy-
3-methylglutaryl-CoA reductase inhibitors, CER and PRA, were
also substrates of all these efflux transporters. The rank order of
the efflux clearance of PRA mediated by each transporter was
the same as that of EG, whereas the contribution of MDR1 to
the efflux of CER was relatively greater than for PRA. This
experimental system is very useful for identifying which trans-
porters are involved in the biliary excretion of organic anions
that cannot easily penetrate the plasma membrane.
Biliary excretion is one of the major pathways for the
elimination of unnecessary compounds from blood circula-
tion. In the common process of hepatic clearance, compounds
are taken up into liver, converted to more hydrophilic metab-
olites by metabolizing enzymes responsible for oxidation
(e.g., cytochrome P450) and/or conjugation (e.g., UDP-glucu-
ronosyl transferases and sulfotransferases), and subse-
quently excreted into bile. Several kinds of ATP-binding cas-
sette (ABC) transporters on the bile canalicular membrane
play an important role in this biliary excretion. It is generally
accepted that multidrug resistance-associated protein 2
(MRP2/ABCC2) is responsible for the biliary excretion of a
wide variety of organic anions including glutathione and
glucuronide conjugates (Suzuki and Sugiyama, 1998; Konig
et al., 1999). This has been proven by comparing the trans-
port activity across the bile canalicular membrane between
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normal and Mrp2-deficient rats such as Eisai hyperbiliru-
binemic rats (EHBR) or TR rats (Suzuki and Sugiyama,
1998; Konig et al., 1999).
Recently, it has been found that some organic anions can
also be substrates of other ABC transporters. Multidrug re-
sistance 1 (MDR1/ABCB1) preferentially accepts hydropho-
bic cationic or neutral compounds (Tanigawara, 2000; Varadi
et al., 2002). However, Cvetkovic et al. (1999) reported that
fexofenadine, an anionic nonsedating antihistamine, could be
transported by human MDR1 (Cvetkovic et al., 1999). It has
also been reported that estradiol-17-D-glucuronide (EG) is a
substrate of MDR1 as well as MRP2 in humans (Huang et al.,
1998). Regarding the sulfated conjugates, we previously
found that the biliary excretion clearance of the sulfates of
6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)
benzothiazole (E3040) and liquiritigenin were excreted into
bile in EHBR to the same extent as in Sprague-Dawley rats
(Shimamura et al., 1994; Takenaka et al., 1995), suggesting
that biliary excretion of sulfate conjugates is not mainly
mediated by Mrp2 in rats. Suzuki et al. (2003) demonstrated
that breast cancer resistance protein (BCRP/ABCG2) accepts
various kinds of organic anions and preferentially transports
sulfate conjugates (Suzuki et al., 2003). Taking into consid-
eration the finding that MDR1 and BCRP are expressed in
the canalicular membrane (Thiebaut et al., 1987; Maliepaard
et al., 2001) in addition to these other facts, not only MRP2
but also MDR1 and BCRP can be involved in the biliary
excretion of organic anions.
The double-transfected Madin-Darby canine kidney II
(MDCKII) cell lines expressing both organic anion-trans-
porting polypeptide 1B1 (OATP1B1/OATP-C/OATP2) or
OATP1B3 (OATP8) in the basolateral membrane and MRP2
in the apical membrane, have been established as an in vitro
model of hepatic vectorial transport of organic anions in
humans (Cui et al., 2001; Sasaki et al., 2002). In this system,
we can observe clear vectorial transport of bisubstrates for
uptake and efflux transporters from the basal to the apical
side compared with that in the opposite direction. The ad-
vantage of this double transfectant system is that it is able to
evaluate the transport activities of apical transporters more
sensitively compared with membrane vesicles. For example,
with pravastatin (PRA), an anionic HMG-CoA reductase in-
hibitor, the ATP-dependent uptake is very small in human
canalicular membrane vesicles (Niinuma et al., 1999),
whereas the transcellular transport activity of PRA in
OATP1B1/MRP2 double transfectant is large enough to ob-
serve its saturation kinetics (Sasaki et al., 2002).
In the present study, we constructed new double transfec-
tants, expressing OATP1B1/MDR1 and OATP1B1/BCRP,
and investigated the transcellular transport of organic an-
ions to determine which transporters are involved in the
biliary excretion. OATP1B1 is exclusively expressed in hu-
man liver and accepts many kinds of organic anions (Abe et
al., 1999; Hsiang et al., 1999; Konig et al., 2000), and very
recently, Hirano et al. (2004) showed that pitavastatin and
EG are mainly taken up by OATP1B1 across the human
basolateral membrane (Hirano et al., 2004). Accordingly, li-
gands can efficiently reach the efflux transporters from the
intracellular compartment via OATP1B1, which makes this
system useful for the characterization of the efflux transport
of organic anions on the bile canalicular membranes. We
investigated the transcellular transport of the following or-
ganic anions, EG and estrone-3-sulfate (ES), and HMG-CoA
reductase inhibitors cerivastatin (CER) and PRA, to examine
whether these compounds exhibited vectorial basal-to-apical
transport in each double transfectant or not.
Materials and Methods
Materials. [3H]EG (1.6 TBq/mmol) and [3H]ES (2.2 TBq/mmol)
were purchased from PerkinElmer Life and Analytical Sciences (Bos-
ton, MA). [3H]CER (0.18 TBq/mmol) was synthesized by Hartmann
Analytic GmbH (Braunschweig, Germany). [3H]PRA (1.6 TBq/mmol)
was kindly donated by Sankyo Co. Ltd. (Tokyo, Japan). Unlabeled
CER was kindly donated by Bayer AG (Wuppertal, Germany).
pEB6CAGMCS/SRZeo was kindly donated by Dr. Miwa (Tsukuba
University, Tsukuba, Japan) (Tanaka et al., 1999). Parental
MDCKII cells and MDCKII cells expressing human MRP2 (Evers et
al., 1998) and MDR1 were kindly provided by Dr. Piet Borst (The
Netherlands Cancer Institute, Amsterdam, The Netherlands). All
other chemicals were commercially available and of reagent grade.
Construction of Plasmid Vector. Previously cloned human
OATP1B1 cDNA in pcDNA3.1/Zeo () vector (Iwai et al., 2004) was
subcloned into the NotI and XhoI sites of pEB6CAGMCS/SRZeo
vector, which is an Epstein-Barr virus-based vector, and the sub-
cloned gene was localized and replicated in the episome and not
integrated into the genome of the host cells (Tanaka et al., 1999).
Cell Culture and Transfection of Expression Vector. Paren-
tal MDCKII cells and MDCKII cells expressing human MRP2 or
MDR1 were cultured in Dulbecco’s modified Eagle’s medium (low
glucose version) (Invitrogen, Carlsbad, CA) with 10% fetal bovine
serum (Sigma-Aldrich, St. Louis, MO) and 1% antibiotic-antimycotic
solution (Sigma-Aldrich) at 37°C under 5% CO2. The transporter
cDNA in the episomal expression vector was transfected into
MDCKII cells using FuGENE6 reagent (Roche Diagnostics Co., In-
dianapolis, IN). At 50% confluence, cells on six-well plates were
exposed to serum-free Dulbecco’s modified Eagle’s medium contain-
ing plasmid and FuGENE6 according to the manufacturer’s instruc-
tion. At 6 h after the initiation of transfection, the plasmid-Fu-
GENE6 solution was replaced with the normal culture medium. The
transfected MDCKII cells were selected with Zeocin (700 g/ml;
Invitrogen).
Construction of Human BCRP-Expressing Cells. For con-
structing MDCKII cells expressing human BCRP, MDCKII cells
were infected with recombinant adenoviruses containing human
BCRP cDNA (Kondo et al., 2004) at 200 multiplicity of infection, 48 h
prior to all experiments. The virus titer was determined as described
previously (Kondo et al., 2004).
Western Blot Analysis. For Western blot analysis, crude mem-
brane was prepared from MDCKII cells according to the method of
the previous report (Gant et al., 1991). After the crude membrane
was suspended in PBS, it was frozen in liquid N2 and stored at –80°C
until used. The protein concentrations in the crude membrane vesi-
cles prepared from MDCKII cells were determined by the method of
Lowry with bovine serum albumin as a standard. The membrane
fraction was dissolved in 3 SDS sample buffer (New England Bio-
labs, Beverly, MA) with -mercaptoethanol and loaded onto a 7%
SDS-polyacrylamide electrophoresis gel with a 4.4% stacking gel.
The molecular weight was determined using a prestained protein
marker (New England Biolabs). Proteins were transferred electro-
phoretically to a polyvinylidene difluoride membrane (Pall, East
Hills, NY) using a blotter (Trans-blot; Bio-Rad, Hercules, CA) at 15
V for 1 h. The membrane was blocked with Tris-buffered saline with
0.05% Tween 20 (TTBS) and 5% skimmed milk overnight at 4°C.
After washing with TTBS, the membrane was incubated at room
temperature in TTBS with 1000-fold diluted anti-OATP1B1 poly-
clonal antibody (Alpha Diagnostic International Inc., San Antonio,
TX) for 1 h, 125-fold diluted monoclonal antibody against MRP2
(M2III-6; Alexis Biochemicals, Gruenberg, Germany) for 2 h, 100-fold
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diluted monoclonal antibody against MDR1 (C219; Signet Laborato-
ries, Inc., Dedham, MA) for 1 h, or 200-fold diluted monoclonal
antibody against BCRP (BXP-21; Kamiya Biomedical Company, Se-
attle, WA) for 2 h. For the detection of each transporter, the mem-
brane was placed in contact with 2500-fold diluted donkey anti-
rabbit (OATP1B1) or anti-mouse IgG (MRP2, MDR1, and BCRP)
conjugated with the horseradish peroxidase (Amersham Biosciences
Inc., Piscataway, NJ) for 1 h in TTBS. The band was detected using
an ECL Plus Western blotting starter kit (Amersham Biosciences
Inc.), and its intensity was quantified in a luminescent image ana-
lyzer (LAS-3000 mini; Fuji Film Corp., Tokyo, Japan).
Immunocytochemical Staining. For immunocytochemical
staining, transfectants were plated at a density of 5  105 cells in
12-well plates, 96 h prior to the experiments. Sodium butyrate (5
mM) was added to the culture medium 1 day before the experiments.
After fixation with methanol at –20°C for 10 min and permeabiliza-
tion in 1% Triton X-100 in PBS at room temperature for 10 min, cells
were incubated for 1 h at room temperature with 50-fold diluted
anti-OATP1B1 rabbit serum, which was raised in rabbits against the
21 amino acids at the carboxyl terminus of the deduced OATP1B1
sequence (ESLNKNKHFVPSAGADSETHC), 40-fold diluted mono-
clonal antibody against MRP2 (M2III-6), 40-fold diluted monoclonal
antibody against MDR1 (C219), or 40-fold diluted monoclonal anti-
body against BCRP (BXP-21). Then, cells were washed with PBS
three times and incubated for 1 h at room temperature with 250-fold
diluted goat anti-rabbit IgG Alexa 488 (Molecular Probes Inc., Eu-
gene, OR) for OATP1B1 or 250-fold diluted goat anti-mouse IgG
Alexa 568 (Molecular Probes Inc.) for MRP2, MDR1, and BCRP.
Nuclei were stained with 250-fold diluted TO-PRO-3 iodide (Molec-
ular Probes Inc.). The localization was visualized by confocal laser
microscopy (Zeiss LSM-510; Carl Zeiss Inc., Thornwood, NY).
Transcellular Transport Study. The transcellular transport
study was performed as reported previously (Sasaki et al., 2002).
Briefly, MDCKII cells were grown on Transwell membrane inserts
(6.5-mm diameter, 0.4-m pore size; Corning Coster, Bodenheim,
Germany) at confluence for 3 days, and the expression level of trans-
porters was induced with 5 mM sodium butyrate for 24 h before the
transport study. Cells were first washed with Krebs-Henseleit buffer
(118 mM NaCl, 23.8 mM NaHCO3, 4.83 mM KCl, 0.96 mM KH2PO4,
1.20 mM MgSO4, 12.5 mM HEPES, 5.0 mM glucose, and 1.53 mM
CaCl2 adjusted to pH 7.4) at 37°C or 4°C. Subsequently, radiolabeled
substrates were added in Krebs-Henseleit buffer either to the apical
compartments (250 l) or to the basolateral compartments (1 ml).
After a designated period, the radioactivity in 100-l medium in the
opposite compartments was measured in a liquid scintillation
counter (LS 6000SE; Beckman Coulter, Fullerton, CA). At the end of
the experiments, the cells were washed three times with 1.5 ml of
ice-cold Krebs-Henseleit buffer and solubilized in 500 l of 0.2 M
NaOH. After addition of 100 l of 1 M HCl, 450-l aliquots were
transferred to the liquid scintillation counter for determination of
radioactivity. Fifty-microliter aliquots of cell lysate were used to
determine protein concentrations by the method of Lowry with bo-
vine serum albumin as a standard.
Calculation of the Transport Activities of Recombinant
MRP2, MDR1, and BCRP across the Double Transfectants.
The apparent efflux clearance across the apical membrane
(PSapical, x°C) at each temperature (37°C or 4°C) was calculated by
dividing the steady-state velocity for the transcellular transport
(Vtranscellular, x°C) of compounds determined over 2 h by the cellular
concentration (Ccell, x°C) of the compounds determined at the end of
the experiments (over 2 h) at each temperature (37°C or 4°C). The
steady-state velocity for the transcellular transport was calculated
by dividing the basal-to-apical transport amount at 2 h (Xx°C) when
the steady-state condition was maintained (see Results) by 120 min.
Then, to evaluate the activity of transporter-mediated transcellular
transport, PSapical, 4°C, the clearance at 4°C (at this temperature the
active transport systems are not functional), was subtracted from
PSapical, 37°C. Moreover, since some endogenous efflux transporters
have been reported to be expressed in MDCKII cells (Goh et al., 2002;
Guo et al., 2002), the specific transport activity across the apical
Fig. 1. Western blot analysis of OATP1B1, MRP2, MDR1, and BCRP in
crude membrane vesicles obtained from MDCKII transfectants. Crude
membrane prepared from MDCKII transfectants was separated by SDS-
polyacrylamide gel electrophoresis. OATP1B1 was detected using poly-
clonal antibody against the carboxyl terminus of human OATP1B1 (A).
MRP2, MDR1, and BCRP were detected using monoclonal antibody
against the linker region of human MRP2 (B), MDR1 (C), and BCRP (D),
respectively. The amount of protein applied to each lane in panel (A), (B),
(C), and (D) was 100, 2, 20, and 0.25 g. C, S1–4, W1–3 represent
vector-transfected MDCKII cells, single-transfected cells (S1, OATP1B1;
S2, MRP2; S3, MDR1; S4, BCRP), and double-transfected cells (W1,
OATP1B1/MRP2; W2, OATP1B1/MDR1; W3, OATP1B1/BCRP). Arrows
represent the specific bands for OATP1B1.
Fig. 2. Immunolocalization of recombinant OATP1B1, MRP2, MDR1, and
BCRP in MDCKII cells. MDCKII cells transfected with empty vector (A),
OATP1B1 (B), MRP2 (C), MDR1 (D), BCRP (E), both OATP1B1 and
MRP2 (F), both OATP1B1 and MDR1 (G), and both OATP1B1 and BCRP
(H) were stained with polyclonal antiserum against human OATP1B1
(green fluorescence, A–H), monoclonal antibody against human MRP2
(red fluorescence, A–C, and F), human MDR1 (red fluorescence, A, B, D,
and G) and human BCRP (red fluorescence, A, B, E, and H). A and B show
the staining with antiserum against human OATP1B1 and MDR1. The
results were similar to the staining with antiserum against human
OATP1B1/MRP2 or OATP1B1/BCRP (data not shown). Nuclei were
stained with TO-PRO-3 (blue fluorescence). Pictures are single optical
sections (x,y) (center) with xz (top) and yz (right) projections, respectively.
Bar  20 m.
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membrane (TA) mediated by exogenously expressed efflux transport-
ers was calculated by subtracting the transporter-mediated clear-
ance in each double transfectant from that in the single transfectant





TA  (PSapical,37°C,double  PSapical,4°C,double) 
(PSapical,37°C,single  PSapical,4°C,single) (2)
Results
Expression of Human OATP1B1, MRP2, MDR1, and
BCRP in MDCKII Cells. The expression of OATP1B1,
MRP2, MDR1, and BCRP in double transfectants was con-
firmed by Western blot analysis (Fig. 1). Two major bands,
which appeared at 83 and 62 kDa, could be detected in all
kinds of OATP1B1-transfected cells (Fig. 1A), as shown pre-
viously (Konig et al., 2000). We were able to clearly detect
human MRP2, MDR1, and BCRP with apparent molecular
masses of about 190, 170, and 70 kDa (Fig. 1, B–D). The band
also reacted slightly with the C219 antibody in wild-type
MDCKII cells (Fig. 1C).
Localization of Recombinant Human OATP1B1,
MRP2, MDR1, and BCRP. The cellular localization of the
recombinant transporters in each transfectant was con-
firmed by confocal laser scanning microscopy. OATP1B1 was
localized in the basolateral membrane (Fig. 2, B and F–H),
whereas MRP2 and MDR1 were localized in the apical mem-
brane (Fig. 2, C, D, F, and G). BCRP was mainly detected in
the apical membrane, but part of the BCRP was also detected
in the basolateral membrane (Fig. 2, E and H).
Transcellular Transport of EG, ES, CER, and PRA
across the MDCKII Cell Monolayer. Transcellular trans-
port of conjugated steroids EG and ES across the MDCKII
monolayer was determined. As shown in Fig. 3, F–H, the
basal-to-apical transport of EG was approximately 17, 6.7,
and 8.8 times higher than that in the opposite direction in
OATP1B1/MRP2, OATP1B1/MDR1, and OATP1B1/BCRP
double transfectants, respectively, whereas the basal-to-api-
cal flux of EG across the OATP1B1-expressing MDCKII cells
was approximately 2.3 times higher than that in the opposite
direction (Fig. 3B). A symmetrical flux of EG was observed
across the control and MRP2-, MDR1-, and BCRP-expressing
MDCKII cells (Fig. 3, A and C–E). For ES, the basal-to-apical
transport was approximately 2.2-, 3.0-, 10-, and 41-fold
higher than that in the opposite direction in OATP1B1-,
OATP1B1/MRP2-, OATP1B1/MDR1-, and OATP1B1/BCRP-
expressing MDCKII cells, respectively (Fig. 4 B and F–H). On
the other hand, a symmetrical flux of ES was observed across
the control and MRP2-, MDR1-, and BCRP-expressing MD-
CKII cells (Fig. 4, A and C–E). Transcellular transport of two
kinds of HMG-CoA reductase inhibitors, CER and PRA, was
also determined in the MDCKII transfectants. As shown in
Fig. 3. Time profiles for the transcellular transport of [3H]EG across MDCKII monolayers. Transcellular transport of [3H]EG (0.5 M) across MDCKII
monolayers expressing OATP1B1 (B), MRP2 (C), MDR1 (D), BCRP (E), both OATP1B1 and MRP2 (F), both OATP1B1 and MDR1 (G), and both
OATP1B1 and BCRP (H) was compared with that across the control MDCKII monolayer (A). Open and closed circles represent the transcellular
transport in the apical-to-basal and basal-to-apical direction, respectively. Each point and vertical bar represents the mean  S.E. of three
determinations. Where vertical bars are not shown, the S.E. was contained within the limits of the symbol.
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Fig. 5, F–H, the basal-to-apical transport of CER was 3.8, 6.3,
and 3.1 times higher than that in the opposite direction in
OATP1B1/MRP2-, OATP1B1/MDR1-, and OATP1B1/BCRP-
expressing MDCKII cells, respectively, whereas a symmetri-
cal flux of CER was observed across the control and all of the
single transfectants (Fig. 5, A–E). On the other hand, the
basal-to-apical flux of PRA was significantly 3.3-fold higher
than that in the opposite direction only in OATP1B1/MRP2-
expressing MDCKII cells (Fig. 6F). However, in the other cell
lines, the ratio of the basal-to-apical flux to that in the oppo-
site direction was less than two (Fig. 6, A–E, G, and H).
Calculation of the Transport Activities of Recombi-
nant MRP2, MDR1, and BCRP across the Apical Mem-
brane of the Double Transfectants. To estimate quanti-
tatively the transport activity by the recombinant
transporters across the apical membrane, the clearance to
the apical compartment from cells (TA) was determined as
described under Materials and Methods. The clearance for
EG was 3.56  0.07, 0.420  0.026, and 0.383  0.059 in
OATP1B1/MRP2-, OATP1B1/MDR1-, and OATP1B1/BCRP-
expressing MDCKII cells, respectively (Fig. 7A). The clear-
ance for ES was 0.268  0.013, 0.351  0.011, and 2.31 
0.02 l/min/mg protein in OATP1B1/MRP2-, OATP1B1/
MDR1-, and OATP1B1/BCRP-expressing MDCKII cells, re-
spectively (Fig. 7B). Regarding the statins, the clearance for
CER was 0.612  0.039, 0.669  0.062, and 0.201  0.007
l/min/mg protein in OATP1B1/MRP2-, OATP1B1/MDR1-,
and OATP1B1/BCRP-expressing MDCKII cells, respectively
(Fig. 7C), whereas the clearance for PRA was 3.75  0.112,
0.393  0.097, and 0.194  0.087 l/min/mg protein, respec-
tively (Fig. 7D).
Discussion
In the present study, we constructed new double transfec-
tants expressing OATP1B1/MDR1 and OATP1B1/BCRP and
observed the transcellular transport of four organic anions,
EG and ES (steroid conjugates) and CER and PRA (HMG-
CoA reductase inhibitors), to examine the substrate speci-
ficities and relative transport activities of the efflux trans-
porters MDR1, MRP2, and BCRP. Western blot and
immunocytochemical analyses revealed that OATP1B1,
MRP2, and MDR1 were expressed in MDCKII cells and lo-
calized correctly on the basolateral (OATP1B1) and apical
membranes (MRP2 and MDR1), respectively, but BCRP was
localized mainly on the apical membrane and only partially
on the basolateral membrane (Fig. 2). On the other hand, we
could clearly observe significant basal-to-apical vectorial
transport of organic anions in OATP1B1/BCRP double-trans-
fected cells (Figs. 3–5), suggesting that minor expression of
BCRP on the basal side does not affect the observation of the
vectorial transport of substrates with our double transfec-
tant, although basal-to-apical transport was thought to be
partly inhibited by the basal expression of BCRP.
Fig. 4. Time profiles for the transcellular transport of [3H]ES across MDCKII monolayers. Transcellular transport of [3H]ES (0.5 M) across MDCKII
monolayers expressing OATP1B1 (B), MRP2 (C), MDR1 (D), BCRP (E), both OATP1B1 and MRP2 (F), both OATP1B1 and MDR1 (G), and both
OATP1B1 and BCRP (H) was compared with that across the control MDCKII monolayer (A). Open and closed circles represent the transcellular
transport in the apical-to-basal and basal-to-apical direction, respectively. Each point and vertical bar represents the mean  S.E. of three
determinations. Where vertical bars are not shown, the S.E. was contained within the limits of the symbol.
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Then, we performed a transcellular transport study involv-
ing four kinds of organic anions using three types of double
transfectants (Figs. 3–6). The double transfectant is a useful
tool for identifying bisubstrates for uptake and efflux trans-
porters and suitable for high throughput screening (Sasaki et
al., 2002). Another advantage of this system is to character-
ize the function of efflux transporters easily because some
compounds cannot access the efflux transporter from the
intracellular compartment without the aid of uptake trans-
porters. In this study, all test compounds are known to be
substrates of OATP1B1 (Abe et al., 1999; Hsiang et al., 1999;
Shitara et al., 2003), and compounds can interact with efflux
transporters efficiently.
The transcellular transport clearance (PStrans) was deter-
mined by both uptake and efflux clearance as shown in eq. 3.




where PSuptake represents the uptake clearance from the
basal side to the cell, and PSapical and PSbasal represent the
efflux clearance from the cell to the apical side and to
the basal side, respectively. If PSapical is much larger than
PSbasal, which is a typical case when the efflux transporter
can recognize the substrate, PStrans is approximately equal to
PSuptake, which is determined by the function of OATP1B1.
So, the transcellular transport clearance does not always
reflect the function of the efflux transporter. Therefore, to
estimate the relative clearance of each efflux transporter, we
calculated the PSapical values by transcellular clearance from
the basal to apical side normalized by the intracellular ligand
concentration (Fig. 7).
EG was efficiently transported from the basolateral to api-
cal side in all these double transfectants (Fig. 3), and the
efflux clearance of MRP2 was much higher than that of
MDR1 and BCRP (Fig. 7A). We previously reported that
Mrp2 is predominantly involved in the biliary excretion of
EG in rats (Morikawa et al., 2000). It has also been reported
that EG is a substrate of human MDR1 and BCRP (Huang et
al., 1998; Chen et al., 2003).
We were also able to observe the vectorial transcellular
transport of ES in all kinds of double transfectants, and
efflux transporters were able to enhance the basal-to-apical
transport of ES compared with the transport in OATP1B1
single transfectant. BCRP showed the highest efflux clear-
ance of ES among the three transporters (Fig. 7B). Suzuki et
al. (2003) reported that BCRP preferentially transports sul-
fated conjugates (Suzuki et al., 2003), and our results suggest
that the sulfate-conjugated steroid ES could be transported
preferentially by BCRP in our double transfectants compared
with MDR1 and MRP2. This result agrees with the previous
report demonstrating that the biliary excretion of the sul-
fated steroid E3040 sulfate was maintained even in EHBR,
an Mrp2-deficient rat (Takenaka et al., 1995)
HMG-CoA reductase inhibitors (statins) are efficiently
Fig. 5. Time profiles for the transcellular transport of [3H]CER across MDCKII monolayers. Transcellular transport of [3H]CER (0.5 M) across
MDCKII monolayers expressing OATP1B1 (B), MRP2 (C), MDR1 (D), BCRP (E), both OATP1B1 and MRP2 (F), both OATP1B1 and MDR1 (G), and
both OATP1B1 and BCRP (H) was compared with that across the control MDCKII monolayer (A). Open and closed circles represent the transcellular
transport in the apical-to-basal and basal-to-apical direction, respectively. Each point and vertical bar represents the mean  S.E. of three
determinations. Where vertical bars are not shown, the S.E. was contained within the limits of the symbol.
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taken up into the liver, where cholesterol is synthesized (Igel
et al., 2001). Among these statins, PRA, CER, pitavastatin,
and rosuvastatin are reported to be substrates of OATP1B1
(Brown et al., 2001; Nakai et al., 2001; Sasaki et al., 2002;
Shitara et al., 2003; Hirano et al., 2004). The basal-to-apical
flux of CER was significantly higher than that in the opposite
direction in all the double transfectants compared with the
OATP1B1 single transfectant (Fig. 5), suggesting that CER is
a substrate of MRP2, MDR1, and BCRP. A previous report
has demonstrated that the transcellular transport of CER
from the basal to apical side across the MDR1-expressed
MDCK monolayer was significantly greater than that in the
opposite direction (Hirai et al., 2001). We were also able to
obtain reproducible results in the MDR1 single transfectant
(Fig. 5D). On the other hand, the ratio of the basal-to-apical
flux to the apical-to-basal flux of PRA was significantly high
only in the OATP1B1/MRP2 double transfectant, whereas
the flux ratio was only slightly raised in OATP1B1/MDR1
and OATP1B1/BCRP transfectants (Fig. 6). Previous reports
have suggested that the biliary excretion of PRA was mostly
mediated by rat Mrp2 (Yamazaki et al., 1997). Interestingly,
the relative activities of each transporter for PRA were very
similar to those for EG, and previous reports have demon-
strated that Mrp2 is responsible for the biliary excretion of
both PRA and EG in rats, suggesting that PRA and EG may
share the same route of biliary excretion, possibly MRP2.
However, considering the reported species differences in the
expression level of transporters (Ishizuka et al., 1999), we
cannot easily estimate the relative contribution of each efflux
transporter from our own data alone and will need further
analyses in which we compare the expression level of apically
localized transporters in double transfectants and human
liver accurately. In our expression system, we observed a low
degree of MDR1-mediated transport of PRA. Some reports
have shown that PRA does not interact with MDR1 using a
cell system (Hirai et al., 2001; Wang et al., 2001; Sakaeda et
al., 2002). However, it is possible that the intracellular con-
centration of PRA was too low for them to detect MDR1-
mediated efflux of PRA because PRA cannot cross the basal
membrane in the MDR1 single transfectant.
In conclusion, we have constructed new double-transfected
cell lines and determined the substrate specificities and rel-
ative transport activities of MRP2, MDR1, and BCRP for
organic anions. Vectorial transport of EG, ES, CER, and PRA
from the basal to apical side was observed in OATP1B1/
MRP2-, OATP1B1/MDR1-, and OATP1B1/BCRP-expressing
cells. The transport activities of EG and PRA by MRP2 were
the highest, considering that MRP2 may be mainly involved
in the transport of EG and PRA in humans as well as rodents.
In the case of ES, BCRP may play an important role in the
biliary excretion. It is interesting that two kinds of structur-
ally related HMG-CoA reductase inhibitors, PRA and CER,
showed different relative contributions from each trans-
porter as far as biliary excretion is concerned. This system is
Fig. 6. Time profiles for the transcellular transport of [3H]PRA across MDCKII monolayers. Transcellular transport of [3H]PRA (0.5 M) across
MDCKII monolayers expressing OATP1B1 (B), MRP2 (C), MDR1 (D), BCRP (E), both OATP1B1 and MRP2 (F), both OATP1B1 and MDR1 (G), and
both OATP1B1 and BCRP (H) was compared with that across the control MDCKII monolayer (A). Open and closed circles represent the transcellular
transport in the apical-to-basal and basal-to-apical direction, respectively. Each point and vertical bar represents the mean  S.E. of three
determinations. Where vertical bars are not shown, the S.E. was contained within the limits of the symbol.
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useful for the determination of the substrate specificities of
hepatic efflux transporters for hydrophilic organic anions,
which cannot easily be extruded from the cellular membrane.
We can also determine the substrate dependence of the rel-
ative contribution of each transporter using this double-
transfected cell system.
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